Get the Stockscreener App
598.89
0.02%
0.10
After Hours:
599.91
1.02
+0.17%
Argen X Se Adr stock is traded at $598.89, with a volume of 565.22K.
It is up +0.02% in the last 24 hours and up +8.65% over the past month.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
See More
Previous Close:
$598.79
Open:
$599.39
24h Volume:
565.22K
Relative Volume:
1.43
Market Cap:
$36.65B
Revenue:
$2.58B
Net Income/Loss:
$1.06B
P/E Ratio:
36.67
EPS:
16.33
Net Cash Flow:
$-1.28B
1W Performance:
+4.08%
1M Performance:
+8.65%
6M Performance:
-10.03%
1Y Performance:
+17.61%
1-Day Range:
$596.01
$608.28
1-Week Range:
$577.04
$608.28
52-Week Range:
$475.65
$678.21
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-13-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-17-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-12-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-17-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Nov-12-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-05-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Nov-01-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Strong Buy |
| Oct-04-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-06-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jul-25-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-31-23 | Initiated | Scotiabank | Sector Perform |
| Jul-24-23 | Downgrade | UBS | Buy → Neutral |
| Jul-17-23 | Resumed | Evercore ISI | Outperform |
| Jun-15-23 | Initiated | Societe Generale | Sell |
| May-31-23 | Initiated | UBS | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-07-22 | Initiated | William Blair | Outperform |
| Oct-12-22 | Initiated | Oppenheimer | Perform |
| Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-22 | Resumed | Stifel | Buy |
| May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-23-21 | Initiated | Deutsche Bank | Hold |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-18-21 | Initiated | UBS | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-23-21 | Initiated | Redburn | Neutral |
| Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
| Feb-10-20 | Initiated | BofA/Merrill | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-22-19 | Initiated | JP Morgan | Overweight |
| Sep-27-19 | Initiated | Wells Fargo | Market Perform |
| Sep-16-19 | Resumed | Cowen | Outperform |
| Jun-28-19 | Initiated | Robert W. Baird | Outperform |
| Jan-18-19 | Resumed | SunTrust | Buy |
| Jan-04-19 | Initiated | Morgan Stanley | Overweight |
| Dec-17-18 | Initiated | Goldman | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Jun-29-18 | Initiated | Nomura | Buy |
| Apr-09-18 | Initiated | SunTrust | Buy |
| Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Morgan Stanley assumes coverage on argenx stock with Overweight rating - Investing.com
Argenx stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Argenx stock falls after FDA flags serious risk signal with Vyvgart - Investing.com
argenx SE’s SWOT analysis: biotech stock’s growth potential and challenges - Investing.com
argenx ADR Shows Market Leadership With Jump To 84 RS Rating - Investor's Business Daily
10 Stocks Analysts Are Upgrading Today - Insider Monkey
Argenx Earnings: Vyvgart Delivers Strong Sales Growth; Prefilled Syringe Expands Patient Access - Morningstar
Metric Analysis: Argen X SE ADR (ARGX)’s Key Ratios in the Limelight - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
Biotech Tumbles. Why Its Sales Beat Wasn't Enough. - Investor's Business Daily
argenx ADR earnings beat by $0.34, revenue topped estimates - Investing.com Nigeria
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Argenx Stock Extends Rally In A Base As Earnings Loom - Investor's Business Daily
argenx ADR Earns Relative Strength Rating Upgrade - inkl
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating By Investing.com - Investing.com South Africa
Biotech Leader Surges On 'Best-Case Scenario' For Key Drug - Investor's Business Daily
Guggenheim maintains Buy on Argenx stock, target at $1,100 - Investing.com India
Guggenheim maintains Buy on Argenx stock, target at $1,100 By Investing.com - Investing.com South Africa
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating - Investing.com India
Stifel maintains $780 target on argenx stock after FDA nod - Investing.com
Stocks To Watch: argenx ADR Sees RS Rating Jump To 91 - Investor's Business Daily
Bernstein double upgrades Argenx to "outperform," raises price target to €755 By Investing.com - Investing.com South Africa
Bernstein double upgrades Argenx to "outperform," raises price target to €755 - Investing.com
Bernstein raises argenx stock rating, hikes target to EUR755 - Investing.com
TD Cowen maintains argenx stock with $761 target, bullish outlook - Investing.com India
TD Cowen maintains argenx stock with $761 target, bullish outlook By Investing.com - Investing.com South Africa
Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target - Investing.com
Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target By Investing.com - Investing.com South Africa
Guggenheim raises argenx stock target to $1,100 on growth outlook - Investing.com India
argenx SE ADR to Host Earnings Call - ACCESS Newswire
Argenx Publishes Long-Term Data At The American Academy Of Neurology 2025 Annual Meeting - Marketscreener.com
Why This Biotech Tumbled For A Second Straight Day - Investor's Business Daily
Argenx Benefits From Multiple Approved Indications of Vyvgart and Strong Uptake - Morningstar
Argenx's Q4 Sales Backed by Vyvgart's Growth, Oppenheimer Says -February 28, 2025 at 11:05 am EST - Marketscreener.com
H.C. Wainwright lifts argenx stock price target to $720 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts argenx stock price target to $720 - Investing.com
Argenx stock target raised to $701 by JMP on VYVGART strength - Investing.com South Africa
Argenx stock target lifted to $761 by TD Cowen, maintains buy - Investing.com India
Argenx’s VYVGART Franchise Drives Strong Performance and Growth Prospects - TipRanks
argenx ADR earnings beat by $10.57, revenue topped estimates - Investing.com South Africa
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.90%
2.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):